Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The crystal structure of RAS was first solved 25 years ago. In spite of tremendous and sustained efforts, there are still no drugs in the clinic that directly target this major driver of human cancers. Recent success in the discovery of compounds that bind RAS and inhibit signaling has fueled renewed enthusiasm, and in-depth understanding of the structure and function of RAS has opened new avenues for direct targeting. To succeed, we must focus on the molecular details of the RAS structure and understand at a high-resolution level how the oncogenic mutants impair function. Structural networks of intramolecular communication between the RAS active site and membrane-interacting regions on the G-domain are disrupted in oncogenic mutants. Although conserved across the isoforms, these networks are near hot spots of protein–ligand interactions with amino acid composition that varies among RAS proteins. These differences could have an effect on stabilization of conformational states of interest in attenuating signaling through RAS. The development of strategies to target these novel sites will add a fresh direction in the quest to conquer RAS-driven cancers. Clin Cancer Res; 21(8); 1810–8. ©2015 AACR. See all articles in this CCR Focus section, “Targeting RAS-Driven Cancers.”
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 4×
“Within this cohort of structures are covalent inhibitors of KRASG12C (33, 35), a mutant commonly found in lung adenocarcinoma (28), bringing to the forefront the prospect of selectively targeting this specific mutant with minimal effect on wildtype RAS.”
BackgroundInfluentialA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 3×
“Contrary to what is observed in all other oncogenic mutants, the water-mediated network from the g-phosphate to the nucleotide sensing residues in helix 5 is intact in both structures ofRASG12D, and thismay contribute to the effectiveness and frequency of this mutant in human cancers (20, 28).”
BackgroundSelf-citationDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 1×
“Contrary to what is observed in all other oncogenic mutants, the water-mediated network from the g-phosphate to the nucleotide sensing residues in helix 5 is intact in both structures ofRASG12D, and thismay contribute to the effectiveness and frequency of this mutant in human cancers (20, 28).”
BackgroundGEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · cited 2×
“In the absence of binding partners, both switch I and switch II are disordered in solution (11, 61), and they become stabilized by interactions with other proteins (15, 30, 76, 77).”
BackgroundStephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 1×
“The problemof drugging RAS for treatment of human cancers is a major challenge for the academic and industry research communities, and the limited success attained so far has recently converged in a call for renewed efforts to conquer this seemingly insurmountable problem (17, 18).”
BackgroundRas history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490 · cited 2×
“Other compounds for which there are crystal structures are not selective for particular mutants and bind at a site on the outer side of switch II (34, 39).”
BackgroundBrefeldin A Acts to Stabilize an Abortive ARF–GDP–Sec7 Domain Protein Complex
Peyroche, A., Antonny, B., Robineau, S., Acker, J., Cherfils, J., & Jackson, C. L. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80455-4 · Cited by 453 · cited 1×
“Although promotion of protein–protein interaction is not trivial, it is not unprecedented (85) and should be explored in the future.”
Background
Cited by
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
McCormick, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2662 · Cited by 320
“In addition to discussing synthetic lethal screens, the authors of this CCR Focus discuss progress in targeting the KRAS protein directly (5), targeting enzymes involved in KRAS processing and membrane localization (6) and a new aspect of KRAS biology: The effects of KRAS on metabolic pathways and opportunities for th…”
BackgroundKRAS-Mutant non-small cell lung cancer: From biology to therapy
Ferrer, I., Zugazagoitia, J., Herbertz, S., John, W., Paz-Ares, L., & Schmid-Bindert, G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.013 · Cited by 311
Jeong, W.-J., Ro, E. J., & Choi, K.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0049-y · Cited by 220
Metadata
- Authors
- Marcus, K., & Mattos, C.
- Venue
- Clinical Cancer Research
- Published
- 2015-04-14
- Volume
- 21
- Issue
- 8
- Pages
- 1810-1818
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W1974393170
- Cited by
- 75
- References
- 20
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-2148
- The paper
- Marcus, K., & Mattos, C. (2015). Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-2148
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.